Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether metadoxine is effective for improve survival and reduced oxidative stress in patients with severe alcoholic hepatitis.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Prednisone | No Intervention | Prednisone 40 mg daily by mouth during 30 days. | |
| Pentoxifylline | No Intervention | Pentoxifylline 400 mg thrice in day by mouth during 30 days | |
| Prednisone plus metadoxine | Experimental | Prednisone 40 mg daily by mouth plus Metadoxine 500 mg thrice in day by mouth during 30 days. |
|
| Pentoxifylline plus metadoxine | Experimental | Pentoxifylline 400 mg thrice in day by mouth plus Metadoxine 500 mg thrice in day by mouth during 30 days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Prednisone plus Metadoxine | Drug |
| ||
| Pentoxifylline plus Metadoxine |
| Measure | Description | Time Frame |
|---|---|---|
| 30 day-survival | 30 days | |
| Malondialdehyde serum levels | 14 and 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| 3 month-survival | 3 months | |
| 6 month-survival | 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital General de Mexico | Mexico City | D.f. | 06726 | Mexico |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25945012 | Derived | Higuera-de la Tijera F, Servin-Caamano AI, Serralde-Zuniga AE, Cruz-Herrera J, Perez-Torres E, Abdo-Francis JM, Salas-Gordillo F, Perez-Hernandez JL. Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis. World J Gastroenterol. 2015 Apr 28;21(16):4975-85. doi: 10.3748/wjg.v21.i16.4975. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006519 | Hepatitis, Alcoholic |
| ID | Term |
|---|---|
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D008108 | Liver Diseases, Alcoholic |
Not provided
Not provided
| ID | Term |
|---|---|
| D011241 | Prednisone |
| C037845 | metadoxine |
| D010431 | Pentoxifylline |
| ID | Term |
|---|---|
| D011244 | Pregnadienediols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
| D020751 |
| Alcohol-Induced Disorders |
| D019973 | Alcohol-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D013805 | Theobromine |
| D014970 | Xanthines |
| D011688 | Purinones |
| D011687 | Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |